Latest Research Report on Cellular Health Testing Market Growth, Industry Revenue Analysis
The growth of the market is attributed to the increasing adoption of telomere performance programs for leading a healthy life; growing focus on increasing healthy life expectancy (HALE); increasing government focus towards preventive healthcare; rising geriatric population and the subsequent growth in the need for cellular health screening; increasing research activities; growing adoption of the direct-to-consumer approach for the availability of kits; and increasing burden of chronic diseases.
The global cellular health screening market is estimated to reach USD 3.42 billion by 2022 from USD 2.12 billion in 2017, at a CAGR of 10.0% during the forecast period.
+ Market Dynamics
+ Drivers
+ Increasing Adoption of Telomere Performance Programs for Leading A Healthy Life
+ Growing Importance of Healthy Life Expectancy (HALE)
+ Rising Government Focus Towards Preventive Healthcare
+ Rising Geriatric Population and Resultant Growth in the Need for Cellular Health Screening
+ Increasing Research Activities
+ Growing Adoption of Direct-To-Consumer Approach for the Availability of Kits
+ Increasing Burden of Chronic Diseases
Download PDF Brochure @https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=227041930
The global cellular health screening market is segmented into single test panels and multi-test panels. In 2017, the single test panels segment is expected to account for the largest share of the global cellular health screening market. These panels are used to get accurate information about a single biomarker and understand how it affects the health of an individual. The preference for multi-test panels is increasing in the market as they provide results for multiple biomarkers in a single exam.
The global cellular health screening market is segmented into at-home, in-office, and other sample collection sites. The at-home segment is expected to register the highest CAGR during the forecast period. The availability of diagnostic and therapeutic products that can be used by patients at home without assistance from healthcare professionals are expected to boost the demand for cellular health screening in this segment.
The global market is highly competitive with the presence of several small and big players. Prominent players in the cellular heath screening market include Genova Diagnostics (US), Telomere Diagnostics (US), Life Length (Spain), Quest Diagnostics (US), Repeat Diagnostics (Canada), SpectraCell Laboratories (US), Zimetry LLC (US), Cell Science Systems (US), Titanovo, Inc. (US), Segterra, Inc. (US), LabCorp Holdings (US), BioReference Laboratories (US), Immundiagnostik AG (Germany), and Cleveland HeartLab, Inc. (US).
Major Market Developments:
- In 2016, Telomere Diagnostics launched TeloYears, its new telomere test.
- In 2015, SpectraCell announced the expansion of its specialized testing menu to include several new diagnostic panels for cardiometabolic biomarkers, pre-diabetic screening, male and female hormone panels, thyroid, and adrenal function and cardiovascular-related genetic tests.
- In 2016, Life Length partenered with Eastern Biotech & Life Sciences to launch telomere tests in GCC countries.
- In 2015, Titanovo launched an at-home, saliva-based telomere testing kit.
In 2017, North America is expected to dominate the global market. Factors such as growing government focus towards preventive healthcare, increasing burden of chronic diseases, increasing research activities, rising geriatric population, and growing number of local players operating in the region are expected to drive the growth of this regional segment.
View complete press release:-https://www.marketsandmarkets.com/PressReleases/cellular-health-screening-test.asp